Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $142.39 billion. The enterprise value is $159.67 billion.
| Market Cap | 142.39B |
| Enterprise Value | 159.67B |
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has increased by 0.68% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | +0.68% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 88.44% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 22.90 and the forward PE ratio is 13.65. Gilead Sciences's PEG ratio is 0.63.
| PE Ratio | 22.90 |
| Forward PE | 13.65 |
| PS Ratio | 5.02 |
| Forward PS | 4.79 |
| PB Ratio | 7.33 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.23 |
| P/OCF Ratio | 14.46 |
| PEG Ratio | 0.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.57, with an EV/FCF ratio of 17.04.
| EV / Earnings | 25.30 |
| EV / Sales | 5.53 |
| EV / EBITDA | 11.57 |
| EV / EBIT | 14.47 |
| EV / FCF | 17.04 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.27.
| Current Ratio | 1.32 |
| Quick Ratio | 0.97 |
| Debt / Equity | 1.27 |
| Debt / EBITDA | 1.79 |
| Debt / FCF | 2.66 |
| Interest Coverage | 11.04 |
Financial Efficiency
Return on equity (ROE) is 33.40% and return on invested capital (ROIC) is 16.02%.
| Return on Equity (ROE) | 33.40% |
| Return on Assets (ROA) | 12.62% |
| Return on Invested Capital (ROIC) | 16.02% |
| Return on Capital Employed (ROCE) | 24.77% |
| Revenue Per Employee | $1.64M |
| Profits Per Employee | $358,580 |
| Employee Count | 17,600 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 3.22 |
Taxes
In the past 12 months, Gilead Sciences has paid $890.00 million in taxes.
| Income Tax | 890.00M |
| Effective Tax Rate | 12.36% |
Stock Price Statistics
The stock price has increased by +52.75% in the last 52 weeks. The beta is 0.35, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +52.75% |
| 50-Day Moving Average | 112.57 |
| 200-Day Moving Average | 103.99 |
| Relative Strength Index (RSI) | 48.79 |
| Average Volume (20 Days) | 6,622,117 |
Short Selling Information
The latest short interest is 19.99 million, so 1.61% of the outstanding shares have been sold short.
| Short Interest | 19.99M |
| Short Previous Month | 22.54M |
| Short % of Shares Out | 1.61% |
| Short % of Float | 1.61% |
| Short Ratio (days to cover) | 3.54 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $28.86 billion and earned $6.31 billion in profits. Earnings per share was $5.01.
| Revenue | 28.86B |
| Gross Profit | 22.67B |
| Operating Income | 11.03B |
| Pretax Income | n/a |
| Net Income | 6.31B |
| EBITDA | 13.80B |
| EBIT | 11.03B |
| Earnings Per Share (EPS) | $5.01 |
Balance Sheet
The company has $6.06 billion in cash and $24.95 billion in debt, giving a net cash position of -$16.98 billion or -$13.68 per share.
| Cash & Cash Equivalents | 6.06B |
| Total Debt | 24.95B |
| Net Cash | -16.98B |
| Net Cash Per Share | -$13.68 |
| Equity (Book Value) | 19.59B |
| Book Value Per Share | 15.84 |
| Working Capital | 3.53B |
Cash Flow
In the last 12 months, operating cash flow was $9.87 billion and capital expenditures -$499.00 million, giving a free cash flow of $9.37 billion.
| Operating Cash Flow | 9.87B |
| Capital Expenditures | -499.00M |
| Free Cash Flow | 9.37B |
| FCF Per Share | $7.55 |
Margins
Gross margin is 78.53%, with operating and profit margins of 38.22% and 21.87%.
| Gross Margin | 78.53% |
| Operating Margin | 38.22% |
| Pretax Margin | 24.95% |
| Profit Margin | 21.87% |
| EBITDA Margin | 47.82% |
| EBIT Margin | 38.22% |
| FCF Margin | 32.46% |
Dividends & Yields
This stock pays an annual dividend of $3.16, which amounts to a dividend yield of 2.75%.
| Dividend Per Share | $3.16 |
| Dividend Yield | 2.75% |
| Dividend Growth (YoY) | 2.61% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 62.66% |
| Buyback Yield | -0.68% |
| Shareholder Yield | 2.07% |
| Earnings Yield | 4.42% |
| FCF Yield | 6.57% |
Analyst Forecast
The average price target for Gilead Sciences is $115.68, which is 0.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $115.68 |
| Price Target Difference | 0.81% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 4.26% |
| EPS Growth Forecast (5Y) | 97.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 3.47 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.47 |
| Piotroski F-Score | 7 |